Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Omni Shoreham Hotel

22 ene 2018 7:00 a.m. - 24 ene 2018 5:00 p.m.

2500 Calvert Street NW, , Washington, DC 20008 , USA

Pharmacovigilance and Risk Management Strategies Conference

Session 7: Update on New Treatments

Session Chair(s)

Stella  Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP

Stella Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP

Strategy

Consultant, United Kingdom

Pharmacovigilance is similar to a detective story. We are trying to determine whether the adverse event is due to a drug, the diseases the patient is being treated for or something intrinsic to the patient. To do this we need an understanding of both the drug mechanisms of action and the context in which drug is used. New classes of treatments are being developed all the time with increasingly complex and specific mechanisms. This session will provide an overview of three emerging therapies from a clinical point of view: CAR-T cells, monoclonal antibodies – targeted therapies and checkpoint inhibitors – and gene therapy.

Speaker(s)

David  Chonzi

Chimeric Antigen Receptor (CAR) T Cell Therapy

David Chonzi

Allogene Therapeutics, United States

Vice President, Head of PV and Epidemiology

Jacques   P. Tremblay, PhD

The New CRISPR/Cas9 Technology

Jacques P. Tremblay, PhD

Laval University, Canada

Deputy Editor, Molecular Therapy and Cell Transplantation;Professor, Department

Jeffrey  Anderson, MD, PhD

Speaker

Jeffrey Anderson, MD, PhD

Bristol-Myers Squibb, United States

HCC Program Lead Oncology Clinical Development

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.